Telangana-based startup Curapod has secured ₹20 crore in funding to expand its wearable, non-invasive pain management devices. The capital will fuel product development, manufacturing scale-up, clinical validation, and wider market reach for its drug-free solutions targeting chronic pain conditions like arthritis, back pain, and neuropathy.
Glimpse:
Curapod’s flagship wearable devices use advanced electrotherapy, heat therapy, and vibration modes to deliver personalized, on-demand pain relief without medications. The ₹20 crore round led by a mix of institutional and angel investors will support R&D for next-gen wearables, regulatory clearances, hospital partnerships, and distribution in Tier-1 and Tier-2 cities. The startup aims to address India’s growing chronic pain burden with affordable, portable alternatives to opioids and frequent doctor visits.
Curapod, a Hyderabad-headquartered healthtech startup specializing in wearable pain management solutions, has raised ₹20 crore in a fresh funding round. The investment will accelerate the company’s mission to bring drug-free, non-invasive pain relief to millions suffering from chronic conditions across India.
Curapod’s devices combine multiple therapeutic modalities transcutaneous electrical nerve stimulation (TENS), targeted heat, and vibration controlled via a smartphone app. Users can customize intensity, duration, and therapy patterns based on their pain profile, making the solution suitable for arthritis, lower back pain, fibromyalgia, post-surgical recovery, and neuropathic pain. The wearables are designed for home use, portability, and long battery life, offering a practical alternative to painkillers and invasive procedures.
The new funding will be used to: Enhance product features with smarter sensors and AI-driven personalization Scale manufacturing to meet rising demand Conduct larger clinical studies to strengthen evidence and gain medical endorsements Expand distribution through e-commerce, pharmacies, hospitals, and orthopedic clinics
Chronic pain affects over 20% of India’s adult population, driving heavy reliance on pain medications with risks of dependency and side effects. Curapod positions itself as a safe, reusable, and cost-effective option that empowers patients to manage pain independently while reducing healthcare system burden.
The round reflects strong investor interest in India’s medtech sector, particularly solutions addressing high-prevalence conditions with scalable, tech-enabled approaches.
“Pain shouldn’t control lives our wearables give people back control without drugs or surgery.”
By
HB Team
